RedChip Visibility Issues Research Update on Aethlon Medical

[Guest guest]

http://money.cnn.com/news/newsfeeds/articles/globenewswire/181860.htm

RedChip Visibility Issues Research Update on Aethlon Medical

January 13, 2010: 01:23 PM ET

ORLANDO, Fla., Jan. 13, 2010 (GLOBE NEWSWIRE) -- RedChip Visibility, a division

of RedChip Companies, Inc., has issued a research update on Aethlon Medical,

Inc. (OTCBB:AEMD), a company developing a therapeutic device to treat acute and

chronic viral infections, biological warfare pathogens, and other conditions by

filtering virus particles and immunosuppressive agents from the blood.

Webber, RedChip Research Analyst, reported:

" During the final months of 2009, Aethlon continued to seek to build value with

the initiation of a pilot production run of Hemopurifier cartridges using Good

Manufacturing Practices, the start of work on less expensive production of the

Hemopurifier's affinity agent in plants, and the establishment of a subsidiary

to develop a non-core, potential use of the device in cancer. "

" Based on the clinical data reported, Aethlon has made development of the

Hemopurifier for the treatment of chronic hepatitis C its core program. During

the final months of the year, the bulk of visible progress took place in

improving manufacturing processes in ways necessary for broad

commercialization. "

Webber continued " We continue to rate Aethlon Medical a Speculative Buy with a

12-month price target of $1.00 per share. According to management, talks

continue with potential partners. As it is not clear when to expect the next

substantial increment of clinical data, we consider news of a partnership,

should that occur, the potential event with the best chance of moving the stock

towards our price target during 2010. "

To receive a complimentary copy of the RedChip Visibility Research Update for

AEMD, please visit: http://www.redchip.com/about/aboutmain.asp?rid=214

To learn more about Aethlon, visit

http://www.redchip.com/visibility/investor.asp?symbol=AEMD.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic filtration devices to improve

the health of individuals afflicted with infectious disease and cancer.

Aethlon's lead product, the Hemopurifier®, is a first-in-class artificial

adjunct to the immune system proven to capture infectious viruses and

immunosuppressive particles from the human circulatory system. The device

targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human

Immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment

countermeasure against bioterror and emerging pandemic threats. The

Hemopurifier® also holds promise in cancer care, as research studies verify

the Hemopurifier® effectively captures immunosuppressive exosomes that are

secreted by tumors to kill-off immune cells. At present, over 65 Hemopurifier®

treatments (representing approximately 260 hours of treatment time) have been

conducted in multi-site studies at the Apollo Hospital, Fortis Hospital, and

Sigma New-Life Hospital in India. The studies enrolled end-stage renal disease

(ESRD) patients infected with either HCV or HIV. In addition to establishing

treatment safety, robust viral load reductions have been reported in both HCV

and HIV infected individuals. Research studies have also demonstrated the

Hemopurifier® is effective in capturing a broad-spectrum of viruses

untreatable with drug therapy, including several of world's deadliest bioterror

and pandemic threats. Beyond therapeutic market opportunities, Aethlon is

leveraging principles underlying the Hemopurifier® technology platform to

establish a pipeline of clinical and research diagnostic products and services.

Additional information regarding Aethlon Medical can be accessed online at

http://www.aethlonmedical.com.

About RedChip Companies, Inc.

RedChip Companies is an international, small-cap research and financial public

relations firm headquartered in Orlando, Florida; with affiliate offices in

Qingdao, China; Paris, and San Diego. RedChip delivers concrete, measurable

results for its clients through its extensive national and international network

of small-cap institutional and retail investors. RedChip has developed the most

comprehensive platform of products and services for small-cap companies,

including: RedChip Research, Traditional Investor Relations, Digital

Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap

TV, Shareholder Intelligence, Social Media and Blogging Services, Webcasts,

and RedChip Radio. To learn more about RedChip's products and services

please visit: http://www.redchip.com/visibility/productsandservices.asp.

" Discovering Tomorrow's Blue Chips Today "

The RedChip Companies, Inc. logo is available at

http://www.globenewswire.com/newsroom/prs/?pkgid=2761

Disclosure

The analysts contributing to this report do not hold any shares of Aethlon

Medical, Inc. (AEMD). RedChip certifies that no part of the analysts'

compensation was, is, or will be, directly or indirectly, related to the

specific recommendation or views expressed by the analyst in the report. The

equity research report(s) are not a recommendation of a solicitation to purchase

or sell any security, nor do they constitute investment advice. AEMD is a client

of RedChip Companies, Inc. and of RedChip Visibility, a division of RedChip

Companies. AEMD paid RedChip Visibility, a division of RedChip Companies, Inc.,

one hundred thousand shares of Rule 144 common stock for RedChip Visibility

Program services, which includes the preparation of the equity research

report(s). The equity research report(s) are prepared for informational purposes

only and are paid for by the company portrayed in the report. Information

contained in the equity research report(s) is obtained from sources believed to

be reliable, but their accuracy and completeness are not guaranteed. RedChip

Companies, Inc., is currently engaged by this company to provide investor

awareness services. Investor awareness services and programs are designed to

help small-cap companies communicate their investment characteristics. These

services may include investor conferences, digital and print distribution of

AEMD investor-related materials, investor road shows and radio programming. AEMD

agreed to pay RedChip Companies, Inc. three hundred thousand shares of Rule 144

common stock for six months of these investor relations services. RedChip

Companies, Inc., employees and affiliates may have positions and affect

transactions in the securities or options of the issuers mentioned herein.

CONTACT: RedChip Companies Inc.

1-800-RED-CHIP (733-2447, Ext. 106)

research@...

http://www.RedChip.com